Improving the Treatment of Chronic Spontaneous Urticaria: What Does the Future Hold?

78-21-631-VL-003-CSU Concept-CTF_500w

Activity Overview

In this activity, a panel of experts discuss the current guideline-recommended treatment approach to chronic spontaneous urticaria (CSU), with a focus on treatment of patients with refractory disease requiring third-line therapy. The panel will also discuss advances in understanding the pathogenesis of disease, the role of type 2 inflammation, and emerging therapies.

0.50 CE Credit(s)
Expires: December 8, 2022

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
  • Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
  • Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Faculty

Jonathan-Bernstein-300px

Jonathan A. Bernstein, MD

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Autumn-Burnette-300px

Autumn Burnette, MD, FACAAI

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Faculty_David M Lang_hi-res_600x620px (1)

David M. Lang, MD

Professor and Chair, Medicine
Department of Allergy and Clinical Immunology
Respiratory Institute
Cleveland, OH